Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JC (2018) Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australasian Psychiatry: Bull Royal Australian New Z Coll Psychiatrists 26:347–357. https://doi.org/10.1177/1039856218762308

Article  Google Scholar 

Weller J, Budson A (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research. https://doi.org/10.1007/10.12688/f1000research.14506.1

Monteiro AR, Barbosa DJ, Remião F, Silva R (2023) Alzheimer’s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol 211:115522. https://doi.org/10.1007/10.1016/j.bcp.2023.115522

Article  CAS  PubMed  Google Scholar 

Twarowski B, Herbet M (2023) Inflammatory processes in Alzheimer’s disease-pathomechanism, diagnosis and treatment: a review. Int J Mol Sci. https://doi.org/10.1007/10.3390/ijms24076518

Article  PubMed  PubMed Central  Google Scholar 

Serý O, Povová J, Míšek I, Pešák L, Janout V (2013) Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol 51:1–9. https://doi.org/10.1007/10.5114/fn.2013.34190

Article  PubMed  Google Scholar 

Zheng Q, Wang X (2025) Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16:83–120. https://doi.org/10.1007/10.1093/procel/pwae026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong W, Xu K, Sun JK et al (2024) The mitochondrial long non-coding RNA LncMtloop regulates mitochondrial transcription and suppresses alzheimer’s disease. EMBO J 43:6001–6031. https://doi.org/10.1038/s44318-024-00270-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olufunmilayo EO, Holsinger RMD (2023) Roles of non-coding RNA in Alzheimer’s disease pathophysiology. Int J Mol Sci. https://doi.org/10.1007/10.3390/ijms241512498

Article  PubMed  PubMed Central  Google Scholar 

Chen X, Ren G, Li Y et al (2022) Level of LncRNA GAS5 and hippocampal volume are associated with the progression of alzheimer’s disease. Clin Interv Aging 17:745–753. https://doi.org/10.2147/cia.S363116

Article  PubMed  PubMed Central  Google Scholar 

Ding Y, Luan W, Shen X, Wang Z, Cao Y (2022) LncRNA BDNF-AS as ceRNA regulates the miR-9-5p/BACE1 pathway affecting neurotoxicity in Alzheimer’s disease. Arch Gerontol Geriatr 99:104614. https://doi.org/10.1007/10.1016/j.archger.2021.104614

Article  CAS  PubMed  Google Scholar 

Lu J, Liu L, Chen J et al (2022) The involvement of LncRNA HOTAIR/miR-130a-3p axis in the regulation of voluntary exercise on cognition and inflammation of alzheimer’s disease. Am J Alzheimer’s Dis Other Dement 37:15333175221091424. https://doi.org/10.1177/15333175221091424

Article  Google Scholar 

Huang B, Ou GY, Zhang N (2024) Identification of key regulatory molecules in the early development stage of Alzheimer’s disease. J Cell Mol Med 28:e18151. https://doi.org/10.1007/10.1111/jcmm.18151

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao C, Hu W, Zhao J, Ni X, Xu Y (2022) LncRNA HCG18 promotes M2 macrophage polarization to accelerate cetuximab resistance in colorectal cancer through regulating miR-365a-3p/FOXO1/CSF-1 axis. Pathol Res Pract 240:154227. https://doi.org/10.1007/10.1016/j.prp.2022.154227

Article  CAS  PubMed  Google Scholar 

Xu YJ, Zhao JM, Ni XF, Wang W, Hu WW, Wu CP (2021) LncRNA HCG18 suppresses CD8(+) T cells to confer resistance to cetuximab in colorectal cancer via miR-20b-5p/PD-L1 axis. Epigenomics 13:1281–1297. https://doi.org/10.1007/10.2217/epi-2021-0130

Article  CAS  PubMed  Google Scholar 

Luo Y, Jiang Y, Zhong T et al (2024) LncRNA HCG18 affects diabetic cardiomyopathy and its association with miR-9-5p/IGF2R axis. Heliyon 10:e24604. https://doi.org/10.1016/j.heliyon.2024.e24604

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Cui Y, Xu S, Li L (2024) LncRNA HCG18 affects aortic dissection through the miR-103a-3p/HMGA2 axis by modulating proliferation and apoptosis of vascular smoothing muscle cells. Clinics (Sao Paulo, Brazil) 79:100400. https://doi.org/10.1007/10.1016/j.clinsp.2024.100400

Article  PubMed  PubMed Central  Google Scholar 

Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746. https://doi.org/10.1016/s1474-4422(07)70178-3

Article  PubMed  Google Scholar 

Zhao KP, Wang XY, Shao MQ, He CY, Yuan FQ (2023) Silencing of long noncoding RNA X-inactive specific transcript alleviates Aβ1-42-induced microglia-mediated neurotoxicity by shifting microglial M1/M2 polarization. Int J Immunopathol Pharmacol 37:3946320231184988. https://doi.org/10.1007/10.1177/03946320231184988

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Fang Z, Lin SL, Schachner M (2025) L1CAM mimetic compound duloxetine improves cognitive impairment in 5xFAD mice and protects Aβ1-42-damaged HT22 cells. Eur J Pharmacol 997:177476. https://doi.org/10.1007/10.1016/j.ejphar.2025.177476

Article  CAS  PubMed  Google Scholar 

Hansson O, Seibyl J, Stomrud E et al (2018) CSF biomarkers of alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in biofinder and ADNI cohorts. Alzheimer’s Dement J Alzheimer’s Assoc 14:1470–1481. https://doi.org/10.1016/j.jalz.2018.01.010

Article  Google Scholar 

Miners JS, Kehoe PG, Love S, Zetterberg H, Blennow K (2019) CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimers Res Ther 11:81. https://doi.org/10.1007/10.1186/s13195-019-0534-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kehoe PG, Al Mulhim N, Zetterberg H, Blennow K, Miners JS (2019) Cerebrospinal fluid changes in the renin-angiotensin system in Alzheimer’s Disease. J Alzheimers Dis 72:525–535. https://doi.org/10.1007/10.3233/jad-190721

Article  CAS  PubMed  Google Scholar 

Lu J, Liu L, Chen J et al (2022) LncRNA HOTAIR in exercise-induced neuro-protective function in alzheimer’s disease. Folia Neuropathol 60:414–420. https://doi.org/10.5114/fn.2022.118961

Article  PubMed  Google Scholar 

Struyfs H, Niemantsverdriet E, Goossens J et al (2015) Cerebrospinal fluid P-Tau181P: biomarker for improved differential dementia diagnosis. Front Neurol 6:138. https://doi.org/10.3389/fneur.2015.00138

Article  PubMed  PubMed Central  Google Scholar 

Oh ES, Rosenberg PB, Rattinger GB, Stuart EA, Lyketsos CG, Leoutsakos JS (2021) Psychotropic medication and cognitive, functional, and neuropsychiatric outcomes in Alzheimer’s Disease (AD). J Am Geriatr Soc 69:955–963. https://doi.org/10.1007/10.1111/jgs.16970

Article  PubMed  Google Scholar 

Prins S, de Kam ML, Teunissen CE, Groeneveld GJ (2022) Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease. Alzheimers Res Ther 14:106. https://doi.org/10.1007/10.1186/s13195-022-01051-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gijs M, Ramakers I, Visser PJ et al (2021) Association of tear fluid amyloid and Tau levels with disease severity and neurodegeneration. Sci Rep 11:22675. https://doi.org/10.1038/s41598-021-01993-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai R, Guo J, Ye XY, Xie Y, Xie T (2022) Oxidative stress: the core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res Rev 77:101619. https://doi.org/10.1007/10.1016/j.arr.2022.101619

Article  CAS  PubMed